Derivatives  ||| S:0 E:12 ||| NNS
of  ||| S:12 E:15 ||| IN
1,4-dihydropyridines  ||| S:15 E:36 ||| CD
as  ||| S:36 E:39 ||| IN
priviledged  ||| S:39 E:51 ||| JJ
structures  ||| S:51 E:62 ||| NNS
and  ||| S:62 E:66 ||| CC
their  ||| S:66 E:72 ||| PRP$
pharmacological  ||| S:72 E:88 ||| JJ
potential  ||| S:88 E:98 ||| JJ
Derivatives  ||| S:98 E:110 ||| NNS
of  ||| S:110 E:113 ||| IN
1,4-dihydropyridine  ||| S:113 E:133 ||| NNP
belong  ||| S:133 E:140 ||| VBP
to  ||| S:140 E:143 ||| TO
group  ||| S:143 E:149 ||| NN
of  ||| S:149 E:152 ||| IN
calcium  ||| S:152 E:160 ||| JJ
channel  ||| S:160 E:168 ||| NN
blockers  ||| S:168 E:177 ||| NNS
and  ||| S:177 E:181 ||| CC
remain  ||| S:181 E:188 ||| VB
large  ||| S:188 E:194 ||| JJ
group  ||| S:194 E:200 ||| NN
of  ||| S:200 E:203 ||| IN
antihypertensive  ||| S:203 E:220 ||| JJ
agents ||| S:220 E:226 ||| NNS
.  ||| S:226 E:228 ||| .
Particular  ||| S:228 E:239 ||| JJ
chemical  ||| S:239 E:248 ||| NN
structure  ||| S:248 E:258 ||| NN
and  ||| S:258 E:262 ||| CC
presence  ||| S:262 E:271 ||| NN
of  ||| S:271 E:274 ||| IN
highly  ||| S:274 E:281 ||| RB
reactive  ||| S:281 E:290 ||| JJ
binding  ||| S:290 E:298 ||| JJ
groups  ||| S:298 E:305 ||| NNS
make  ||| S:305 E:310 ||| VBP
1,4-dihydropyridines  ||| S:310 E:331 ||| RB
privileged  ||| S:331 E:342 ||| JJ
structures ||| S:342 E:352 ||| NNS
,  ||| S:352 E:354 ||| ,
which  ||| S:354 E:360 ||| WDT
can  ||| S:360 E:364 ||| MD
be  ||| S:364 E:367 ||| VB
modified  ||| S:367 E:376 ||| VBN
and  ||| S:376 E:380 ||| CC
change  ||| S:380 E:387 ||| VB
their  ||| S:387 E:393 ||| PRP$
pharmacological  ||| S:393 E:409 ||| JJ
effects ||| S:409 E:416 ||| NNS
.  ||| S:416 E:418 ||| .
This  ||| S:418 E:423 ||| DT
fact  ||| S:423 E:428 ||| NN
applies  ||| S:428 E:436 ||| VBZ
to  ||| S:436 E:439 ||| TO
new  ||| S:439 E:443 ||| JJ
derivatives  ||| S:443 E:455 ||| NNS
as  ||| S:455 E:458 ||| IN
well  ||| S:458 E:463 ||| RB
as  ||| S:463 E:466 ||| IN
metabolites  ||| S:466 E:478 ||| NN
of  ||| S:478 E:481 ||| IN
those  ||| S:481 E:487 ||| DT
drugs ||| S:487 E:492 ||| NNS
.  ||| S:492 E:494 ||| .
Particularly  ||| S:494 E:507 ||| RB
interesting  ||| S:507 E:519 ||| JJ
are  ||| S:519 E:523 ||| VBP
outcomes  ||| S:523 E:532 ||| VBN
of  ||| S:532 E:535 ||| IN
experiments  ||| S:535 E:547 ||| NNS
with  ||| S:547 E:552 ||| IN
metabolites  ||| S:552 E:564 ||| NN
of  ||| S:564 E:567 ||| IN
furnidypine ||| S:567 E:578 ||| NN
,  ||| S:578 E:580 ||| ,
which  ||| S:580 E:586 ||| WDT
tend  ||| S:586 E:591 ||| VBP
to  ||| S:591 E:594 ||| TO
cause  ||| S:594 E:600 ||| VB
different  ||| S:600 E:610 ||| JJ
pharmacological  ||| S:610 E:626 ||| JJ
effect ||| S:626 E:632 ||| NN
,  ||| S:632 E:634 ||| ,
as  ||| S:634 E:637 ||| RB
well  ||| S:637 E:642 ||| RB
as  ||| S:642 E:645 ||| RB
have  ||| S:645 E:650 ||| VB
different  ||| S:650 E:660 ||| JJ
profile  ||| S:660 E:668 ||| NN
of  ||| S:668 E:671 ||| IN
adverse  ||| S:671 E:679 ||| JJ
effects  ||| S:679 E:687 ||| NNS
from  ||| S:687 E:692 ||| IN
mother  ||| S:692 E:699 ||| NN
drug ||| S:699 E:703 ||| NN
.  ||| S:703 E:705 ||| .
Our  ||| S:705 E:709 ||| PRP$
paper  ||| S:709 E:715 ||| NN
concerns  ||| S:715 E:724 ||| NNS
with  ||| S:724 E:729 ||| IN
potential  ||| S:729 E:739 ||| JJ
new  ||| S:739 E:743 ||| JJ
possibilities  ||| S:743 E:757 ||| NNS
of  ||| S:757 E:760 ||| IN
using  ||| S:760 E:766 ||| VBG
derivatives  ||| S:766 E:778 ||| NNS
of  ||| S:778 E:781 ||| IN
1,4-dihydropyridines ||| S:781 E:801 ||| NNP
,  ||| S:801 E:803 ||| ,
as  ||| S:803 E:806 ||| RB
well  ||| S:806 E:811 ||| RB
as  ||| S:811 E:814 ||| IN
their  ||| S:814 E:820 ||| PRP$
metabolites ||| S:820 E:831 ||| NN
,  ||| S:831 E:833 ||| ,
as  ||| S:833 E:836 ||| IN
agents  ||| S:836 E:843 ||| NNS
of  ||| S:843 E:846 ||| IN
more  ||| S:846 E:851 ||| RBR
optimised  ||| S:851 E:861 ||| JJ
effect ||| S:861 E:867 ||| NN
.  ||| S:867 E:869 ||| .
